Aptorum Group Limited (APM)
Stock Price:
$2.46 USD
-0.07 (-2.77%)
Updated December 3, 4:00 PM EST - Market closed
Key Info
| Market Cap |
28.47M |
| Revenue (ttm) |
535,166 |
| Net Income (ttm) |
-18.69M |
| Shares Out |
29.01M |
| EPS (ttm) |
-0.54 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 3 |
| Last Price |
$2.46 |
| Previous Close |
$2.53 |
| Change ($) |
-0.07 |
| Change (%) |
-2.77% |
| Day's Open |
2.53 |
| Day's Range |
2.46 - 2.56 |
| Day's Volume |
199,281 |
| 52-Week Range |
1.22 - 16.00 |
More Stats
| Market Cap |
28.47M |
| Enterprise Value |
28.39M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
29.01M |
| Float |
n/a |
| EPS (basic) |
-0.64 |
| EPS (diluted) |
-0.54 |
| FCF / Share |
-0.49 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
266,777 |
| Short Ratio |
0.59 |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
53.20 |
| PB Ratio |
4.42 |
| Revenue |
535,166 |
| Operating Income |
-18.20M |
| Net Income |
-18.69M |
| Free Cash Flow |
-14.22M |
| Net Cash |
86,797 |
| Net Cash / Share |
0.01 |
| Gross Margin |
-41.66% |
| Operating Margin |
-3,400.52% |
| Profit Margin |
-3,491.80% |
| FCF Margin |
-2,657.06% |
| ROA |
-47.55% |
| ROE |
-84.08% |
| ROIC |
-81.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$13.00*
(428.46% upside)
Low
11.0
Current: $2.46
High
15.0
Target: 13.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 0.54 | 0.38 |
| Revenue Growth | 39.57% | - |
| Gross Profit | -0.26 | 0.07 |
| Operating Income | -18.20 | -10.33 |
| Net Income | -18.69 | -14.83 |
| Shares Outstanding | 29.01 | 27.91 |
| Earnings Per Share | -0.64 | -0.53 |
| Operating Cash Flow | -13.38 | -10.04 |
| Capital Expenditures | -0.84 | -5.65 |
| Free Cash Flow | -14.22 | -15.68 |
| Cash & Equivalents | 6.56 | 27.24 |
| Total Debt | 6.47 | 10.30 |
| Net Cash / Debt | 0.09 | 16.94 |
| Assets | 23.95 | 45.07 |
| Liabilities | 9.10 | 12.33 |
| Book Value | 16.36 | 33.11 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aptorum Group Limited |
| Employees |
36 |
Stock Information
| Ticker Symbol |
APM |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: APM |
| IPO Date |
December 18, 2018 |
Description
Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. Its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.